|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 7272 WISCONSIN AVENUE |
Address2 | |
City | BETHESDA |
State | MD |
Zip Code | 20814 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 3457-12
|
||||||||
|
6. House ID# 315500000
|
TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Brian M. Meyer |
Date | 10/17/2008 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 2642, Iraq War Supplemental Appropriations, support additional appropriations for Food and Drug Administration.
Communications to FDA staff regarding gluten labeling on medications; Risk Communication Advisory Committee meeting; maintaining HFA designation on labeling. Meeting with FDA Chief of Staff; Communication to FDA re: testimony before joint meeting of the Antiviral Drugs Advisory Committee and the Nonprescription Drugs Advisory Committee; Comments to FDA re
concept paper on evaluating proposed drug name submissions. Comments to FDA on content and format labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling; Communication re; nominations to FDA advisory committee
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Meyer |
|
|
|
Joseph |
Hill |
|
|
|
Justine |
Coffey |
|
|
|
Geralyn |
Trujillo |
|
|
|
Morgan |
Hanson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 6331, Medicare Improvements for Patients and Providers Act of 2008, Title I Section 182, provision that revises definition of medically accepted indication for drugs and conflicts of interest. Communication and meetings with CMS staff regarding compendia recognition. Presentation and written testimony before CMS' Ambulatory Payment Classification Panel regarding pharmacy overhead
Comments to CMS re: Hospital Outpatient Prospective Payment System and 2009 Payment rates. Communications with CMS re:
Conditions of Participation and Interpretive Guidance regarding standing orders and protocols. Comments to CMS re: e-prescribing exemption for computer generated facsimile transmissions.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Meyer |
|
|
|
Joseph |
Hill |
|
|
|
Justine |
Coffey |
|
|
|
Geralyn |
Trujillo |
|
|
|
Morgan |
Hanson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
S. 901, Health Centers Renewal Act of 2007, include pharmacists as eligible for loan forgiveness programs of the National Health Service Corps. S.2708, Caring for an Aging America Act of 2008, include pharmacists in geriatric training program.
Proposed legislation to create an academic counterdetailing program on prescription drugs. Outlined potential role of the pahrmacist. S. 2932, Poison Center Support, Enhancement, and Awareness of 2008, support all provisions. H.R. 5491, The
Pharmacy Technician Training and Registration Act of 2008; all provisions.
FDA: Communicated policy concerning National Drug Code number system and need for improvements. DEA: proposed rule concerning electronic prescriptions for controlled substances. Comments to the Office of the Natinal Coordinator for Health Information Technology re: Draft Medication Gaps and Draft Order Sets.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Meyer |
|
|
|
Joseph |
Hill |
|
|
|
Justine |
Coffey |
|
|
|
Geralyn |
Trujillo |
|
|
|
Morgan |
Hanson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |